CA2704981A1 - Aldh-2 inhibitors in the treatment of psychiatric disorders - Google Patents

Aldh-2 inhibitors in the treatment of psychiatric disorders Download PDF

Info

Publication number
CA2704981A1
CA2704981A1 CA2704981A CA2704981A CA2704981A1 CA 2704981 A1 CA2704981 A1 CA 2704981A1 CA 2704981 A CA2704981 A CA 2704981A CA 2704981 A CA2704981 A CA 2704981A CA 2704981 A1 CA2704981 A1 CA 2704981A1
Authority
CA
Canada
Prior art keywords
chromen
hydroxyphenyl
phenyl
methoxy
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2704981A
Other languages
English (en)
French (fr)
Inventor
Ivan Diamond
David Overstreet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2704981A1 publication Critical patent/CA2704981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA2704981A 2007-11-06 2008-11-06 Aldh-2 inhibitors in the treatment of psychiatric disorders Abandoned CA2704981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98591107P 2007-11-06 2007-11-06
US60/985,911 2007-11-06
PCT/US2008/082643 WO2009061924A2 (en) 2007-11-06 2008-11-06 Aldh-2 inhibitors in the treatment of psychiatric disorders

Publications (1)

Publication Number Publication Date
CA2704981A1 true CA2704981A1 (en) 2009-05-14

Family

ID=40512184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704981A Abandoned CA2704981A1 (en) 2007-11-06 2008-11-06 Aldh-2 inhibitors in the treatment of psychiatric disorders

Country Status (12)

Country Link
US (1) US20090124672A1 (zh)
EP (1) EP2231149A2 (zh)
JP (1) JP2011503095A (zh)
KR (1) KR20100097675A (zh)
CN (1) CN101917987A (zh)
AU (1) AU2008323953A1 (zh)
BR (1) BRPI0820440A2 (zh)
CA (1) CA2704981A1 (zh)
IL (1) IL205578A0 (zh)
MX (1) MX2010005047A (zh)
RU (1) RU2010122970A (zh)
WO (1) WO2009061924A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158810B2 (en) * 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
KR20090033417A (ko) * 2006-07-27 2009-04-03 씨브이 쎄러퓨틱스, 인코포레이티드 중독의 치료에서의 aldh-2 저해제
KR20100130589A (ko) * 2008-01-24 2010-12-13 질레드 팔로 알토 인코포레이티드 중독 치료에서의 aldh-2 저해제
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
WO1999058124A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
EP1294377B1 (en) * 2000-06-30 2011-10-12 Abdulla Badawy Methods and compositions for the treatment of alcoholism and alcohol dependence
JP4933730B2 (ja) * 2001-05-04 2012-05-16 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
WO2004002470A1 (en) * 2002-06-27 2004-01-08 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of aldh
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
KR20090033417A (ko) * 2006-07-27 2009-04-03 씨브이 쎄러퓨틱스, 인코포레이티드 중독의 치료에서의 aldh-2 저해제
CA2682207A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors

Also Published As

Publication number Publication date
BRPI0820440A2 (pt) 2015-05-26
IL205578A0 (en) 2010-11-30
KR20100097675A (ko) 2010-09-03
AU2008323953A1 (en) 2009-05-14
MX2010005047A (es) 2010-07-28
US20090124672A1 (en) 2009-05-14
EP2231149A2 (en) 2010-09-29
RU2010122970A (ru) 2011-12-20
CN101917987A (zh) 2010-12-15
WO2009061924A2 (en) 2009-05-14
WO2009061924A3 (en) 2009-07-09
JP2011503095A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
CA2704981A1 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
CA2653056A1 (en) Aldh-2 inhibitors in the treatment of addiction
US8158810B2 (en) ALDH-2 inhibitors in the treatment of addiction
EP2588450B1 (en) Napht-2-ylacetic acid derivatives to treat aids
EP2697213B1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
AU2008348372A1 (en) ALDH-2 inhibitors in the treatment of addiction
CZ20013714A3 (cs) Léčivo pro léčení nemocí spojených s receptorem - beta estrogenu
MXPA04000565A (es) Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos.
JP4865785B2 (ja) Cdk阻害剤としての置換1,5−ナフチリジンアゾリジノン
CA2682207A1 (en) Quinazolinone derivatives as aldh-2 inhibitors
US20080207610A1 (en) Aldh-2 inhibitors in the treatment of addiction
AU2012300209B2 (en) ALDH-2 inhibitors in the treatment of addiction
US20130225517A1 (en) Therapeutic Compounds
CN101627024A (zh) 成瘾治疗中的aldh-2抑制剂
WO2003020712A1 (en) Oxadiazolyl-phenoxyalkylthiadiazoles, compositions thereof and methods for their use as anti-picornaviral agents
WO2010064958A2 (ru) Ингибиторы протеинкиназы с, обладающие противовоспалительным, противоаллергическим и противоастматическим действием

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20121106